Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Oxford Biomedica eyes UK supply boost of AstraZeneca's COVID-19 vaccine

share with twitter share with LinkedIn share with facebook
06/08/2020 | 03:24am EDT
FILE PHOTO: Small bottles labeled with a

Oxford Biomedica has signed a new manufacturing agreement with a group backed by the UK government to help it scale up production of AstraZeneca's potential COVID-19 vaccine to cater to demand in the United Kingdom and Europe.

The gene and cell therapy firm said on Monday it agreed to a five-year partnership with the Vaccines Manufacturing and Innovation Centre (VMIC) for equipment at its facility in Oxford, UK which would also help it make other vaccines.

While it is unclear if vaccines will work against the disease caused by the new coronavirus, dozens of companies are in the race to develop one amid ongoing trials. AstraZeneca said last week it was targeting two billion doses of its shot, AZD1222.

"This new partnership between VMIC and Oxford Biomedica ... will specifically help ensure that we have the right skills in place to manufacture a vaccine as soon as one is available," said Kate Bingham, Chair of the UK Vaccine Taskforce.

AstraZeneca's vaccine, a type known as a recombinant viral vector vaccine, uses a weakened version of the common-cold virus spiked with proteins from the novel coronavirus to generate a response from the body's immune system.

The drugmaker in May partnered with Oxford Biomedica, spun off from the University of Oxford in 1995, for its experimental COVID-19 vaccine.

VMIC was founded in 2018 by the University of Oxford, Imperial College and London School of Hygiene and Tropical Medicine, and it receives funding from the UK Government's Industrial Strategy Challenge Fund.

Oxford Biomedica shares were up 3% at 798 pence in early trading.

(Reporting by Pushkala Aripaka in Bengaluru; editing by Uttaresh.V)

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.15% 7943 Delayed Quote.4.42%
AT HOME GROUP INC. 3.09% 22.72 Delayed Quote.313.09%
JUST GROUP PLC -0.68% 46.64 Delayed Quote.-40.96%
OXFORD BIOMEDICA PLC 3.67% 819 Delayed Quote.26.98%
VECTOR INC. -0.95% 209 End-of-day quote.-36.47%
VECTOR INC. -0.88% 1009 End-of-day quote.-5.35%
WILL GROUP, INC. 1.55% 852 End-of-day quote.-31.95%
share with twitter share with LinkedIn share with facebook
All news about ASTRAZENECA PLC
12:16aTo Find a Coronavirus Vaccine, GlaxoSmithKline Is Bonding With Its Biggest Co..
10/23ASTRAZENECA : says its Oxford vaccine deal allows it to add up to 20% of manufac..
10/23AstraZeneca resumes U.S. COVID-19 vaccine trial and next week J&J prepares to..
10/23NEWS HIGHLIGHTS : Top Company News of the Day
10/23NEWS HIGHLIGHTS : Top Company News of the Day
10/23Health Care Up After Final Presidential Debate -- Health Care Roundup
10/23ASTRAZENECA : Covid-19 Vaccine Trial From AstraZeneca, Oxford Can Resume in U.S...
10/23ASTRAZENECA : Pivotal Studies of Covid-19 Vaccines From AstraZeneca, J&J Resumin..
10/23ASTRAZENECA : Says FDA Authorises Restart Of COVID-19 Vaccine Trial in U.S.
10/23NEWS HIGHLIGHTS : Top Company News of the Day
More news
Financials (USD)
Sales 2020 26 703 M - -
Net income 2020 3 074 M - -
Net Debt 2020 13 178 M - -
P/E ratio 2020 47,1x
Yield 2020 2,72%
Capitalization 136 B 136 B -
EV / Sales 2020 5,58x
EV / Sales 2021 4,86x
Nbr of Employees 70 600
Free-Float 95,7%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 118,27 $
Last Close Price 103,58 $
Spread / Highest target 50,1%
Spread / Average Target 14,2%
Spread / Lowest Target -36,3%
EPS Revisions
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-0.43%382 391
ROCHE HOLDING AG-5.29%280 884
PFIZER INC.-2.55%212 162
MERCK & CO., INC.-12.23%201 909
NOVARTIS AG-16.78%185 999